Current status of research on fibrates in treatment of primary biliary cholangitis
10.3969/j.issn.1001-5256.2020.02.046
- VernacularTitle:贝特类药物治疗原发性胆汁性胆管炎的研究现状
- Author:
Jing WEI
1
;
Xirun WU
Author Information
1. Department of Gastroenterology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China
- Publication Type:Research Article
- Keywords:
primary biliary cholangitis;
fibric acids;
therapeutics
- From:
Journal of Clinical Hepatology
2020;36(2):442-445
- CountryChina
- Language:Chinese
-
Abstract:
At present, ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are approved by FDA for the treatment of primary biliary cholangitis (PBC). New drugs are urgently needed for the patients who have inadequate response to UDCA or cannot tolerate pruritus, a common side effect of OCA. In recent years, a large number of basic experiments and clinical studies have shown that fibrates have a good clinical effect in the treatment of PBC. This article reviews the advances in the mechanism and clinical application of fibrates in the treatment of PBC.
